TDMS Study 93020-08 Pathology Tables
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
FINAL #1 MICE
Facility: Southern Research Institute
Chemical CAS #: 693-13-0
Lock Date: 03/14/03
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Natural Death 5 5 6 4
Moribund Sacrifice 12 11 4 5
Accidently Killed 1 1 1
Survivors
Terminal Sacrifice 33 32 38 40
Natural Death 1
Moribund Sacrifice 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (42) (47) (42) (47)
Cyst 1 (2%)
Intestine Large, Cecum (46) (45) (44) (47)
Cyst 1 (2%)
Edema 1 (2%)
Intestine Small, Duodenum (46) (46) (44) (47)
Hyperplasia, Lymphoid 1 (2%)
Perforation 1 (2%)
Intestine Small, Jejunum (47) (45) (44) (46)
Inflammation, Focal 1 (2%)
Epithelium, Hyperplasia, Focal 1 (2%)
Peyer's Patch, Hyperplasia, Lymphoid 1 (2%)
Intestine Small, Ileum (46) (44) (45) (47)
Peyer's Patch, Hyperplasia, Lymphoid 1 (2%)
Liver (50) (50) (50) (50)
Angiectasis, Focal 1 (2%) 2 (4%)
Clear Cell Focus 1 (2%)
Congestion 1 (2%)
Eosinophilic Focus 6 (12%) 1 (2%) 6 (12%)
Hematopoietic Cell Proliferation 2 (4%) 1 (2%)
Hyperplasia, Focal, Lymphoid 1 (2%) 2 (4%)
Infiltration Cellular, Polymorphonuclear 1 (2%) 1 (2%)
Infiltration Cellular, Mixed Cell 16 (32%) 9 (18%) 10 (20%) 22 (44%)
Mineralization, Focal 1 (2%)
Necrosis, Focal 1 (2%)
Hepatocyte, Basophilic Focus 1 (2%) 1 (2%) 1 (2%)
Hepatocyte, Clear Cell Focus 3 (6%) 2 (4%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Hepatocyte, Eosinophilic Focus 4 (8%)
Hepatocyte, Karyomegaly 1 (2%)
Hepatocyte, Mixed Cell Focus 2 (4%) 1 (2%) 6 (12%)
Hepatocyte, Necrosis, Focal 3 (6%) 3 (6%) 1 (2%) 1 (2%)
Hepatocyte, Vacuolization Cytoplasmic 5 (10%) 3 (6%) 1 (2%) 5 (10%)
Mesentery (23) (20) (14) (18)
Hemorrhage 1 (7%)
Infiltration Cellular, Lymphoid 1 (4%)
Infiltration Cellular, Mixed Cell 1 (4%)
Inflammation 3 (13%) 5 (25%) 1 (6%)
Artery, Inflammation 1 (6%)
Fat, Necrosis, Focal 17 (74%) 13 (65%) 9 (64%) 15 (83%)
Pancreas (50) (48) (50) (50)
Inflammation, Focal 1 (2%)
Acinus, Atrophy, Diffuse 2 (4%)
Acinus, Atrophy, Focal 1 (2%) 2 (4%) 1 (2%) 3 (6%)
Duct, Cyst, Focal, Multiple 2 (4%) 1 (2%)
Stomach, Forestomach (50) (49) (50) (50)
Diverticulum 1 (2%) 1 (2%)
Erosion 2 (4%) 2 (4%)
Inflammation, Focal 1 (2%) 1 (2%) 1 (2%)
Ulcer 1 (2%) 1 (2%) 2 (4%)
Epithelium, Hyperplasia 4 (8%) 4 (8%) 2 (4%) 1 (2%)
Stomach, Glandular (49) (48) (47) (50)
Erosion 1 (2%)
Glands, Hyperplasia, Focal 1 (2%)
Tooth (1) (1) (1) (2)
Malformation 1 (100%) 1 (50%)
Peridontal Tissue, Inflammation, Chronic 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (49) (50)
Cardiomyopathy 3 (6%) 1 (2%) 1 (2%)
Infiltration Cellular, Polymorphonuclear 1 (2%)
Infiltration Cellular, Mixed Cell 1 (2%)
Inflammation, Chronic, Focal 1 (2%)
Thrombosis 4 (8%) 2 (4%)
Artery, Inflammation, Chronic 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (50)
Accessory Adrenal Cortical Nodule 2 (4%) 1 (2%) 1 (2%) 3 (6%)
Angiectasis 1 (2%)
Cytoplasmic Alteration, Focal 1 (2%) 2 (4%) 1 (2%)
Degeneration, Cystic 1 (2%) 1 (2%) 1 (2%)
Infiltration Cellular, Polymorphonuclear 1 (2%)
Inflammation, Suppurative 1 (2%)
Necrosis, Focal 1 (2%)
Adrenal Medulla (49) (50) (49) (49)
Angiectasis 1 (2%)
Hyperplasia 1 (2%)
Inflammation, Suppurative 1 (2%)
Islets, Pancreatic (50) (49) (50) (50)
Hyperplasia 2 (4%) 1 (2%)
Parathyroid Gland (46) (43) (49) (49)
Cyst 2 (4%) 2 (5%) 1 (2%)
Pituitary Gland (48) (50) (50) (46)
Angiectasis 3 (6%) 1 (2%) 1 (2%) 3 (7%)
Cyst 1 (2%)
Hemorrhage 1 (2%)
Pars Distalis, Cytoplasmic Alteration, Focal 2 (4%) 4 (8%) 1 (2%)
Pars Distalis, Degeneration, Cystic, Focal 1 (2%)
Pars Distalis, Hyperplasia, Focal 3 (6%) 2 (4%) 7 (14%) 3 (7%)
Pars Intermedia, Hyperplasia, Focal 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Cyst 2 (4%) 3 (6%) 1 (2%)
Inflammation, Chronic, Focal 1 (2%)
C-Cell, Hyperplasia 2 (4%)
Follicle, Degeneration, Cystic, Focal 14 (28%) 14 (28%) 18 (36%) 12 (24%)
Follicular Cell, Hyperplasia, Focal 1 (2%) 11 (22%) 9 (18%) 4 (8%)
Follicular Cell, Vacuolization Cytoplasmic,
Focal 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (5) (8) (3) (4)
Mediastinum, Infiltration Cellular, Lymphoid 1 (20%) 1 (25%)
Mediastinum, Inflammation, Suppurative 1 (13%) 1 (25%)
Nasal, Hemorrhage 1 (13%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (46) (48) (48) (47)
Degeneration, Cystic 1 (2%)
Inflammation, Chronic 1 (2%)
Ovary (49) (50) (49) (49)
Angiectasis 2 (4%) 3 (6%) 1 (2%) 1 (2%)
Cyst 14 (29%) 16 (32%) 13 (27%) 18 (37%)
Hemorrhage 2 (4%)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Suppurative 2 (4%) 2 (4%) 2 (4%)
Thrombosis 2 (4%) 1 (2%) 1 (2%)
Bilateral, Cyst 1 (2%)
Bilateral, Inflammation, Suppurative 1 (2%) 1 (2%)
Interstitial Cell, Hyperplasia 1 (2%)
Oviduct (3) (1)
Inflammation, Suppurative 3 (100%)
Uterus (50) (50) (50) (50)
Hemorrhage 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Inflammation, Suppurative 5 (10%) 8 (16%) 6 (12%) 2 (4%)
Thrombosis 1 (2%)
Cervix, Hypertrophy 1 (2%)
Endometrium, Hyperplasia, Cystic 46 (92%) 44 (88%) 47 (94%) 49 (98%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (49)
Hyperplasia 14 (29%) 5 (10%) 10 (20%) 2 (4%)
Lymph Node (11) (13) (10) (10)
Hyperplasia, Lymphoid 1 (10%)
Bronchial, Hyperplasia, Lymphoid 1 (10%)
Iliac, Ectasia 1 (8%) 1 (10%) 3 (30%)
Iliac, Hemorrhage 2 (18%)
Iliac, Hyperplasia, Lymphoid 2 (18%) 2 (15%) 2 (20%) 2 (20%)
Inguinal, Hyperplasia, Lymphoid 1 (9%)
Mediastinal, Ectasia 1 (9%)
Mediastinal, Hemorrhage 1 (8%)
Mediastinal, Hyperplasia 1 (8%)
Mediastinal, Hyperplasia, Lymphoid 1 (9%) 2 (15%) 1 (10%) 3 (30%)
Pancreatic, Hemorrhage 1 (8%)
Pancreatic, Hyperplasia, Lymphoid 1 (9%) 1 (8%) 1 (10%)
Renal, Ectasia 1 (8%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Renal, Hyperplasia, Lymphoid 1 (9%) 1 (8%) 2 (20%)
Lymph Node, Mandibular (47) (49) (49) (48)
Hemorrhage 1 (2%)
Hyperplasia, Lymphoid 6 (13%) 4 (8%) 2 (4%) 1 (2%)
Lymph Node, Mesenteric (47) (48) (49) (50)
Ectasia 1 (2%) 1 (2%) 5 (10%) 2 (4%)
Hematopoietic Cell Proliferation 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia, Lymphoid 3 (6%) 6 (13%) 2 (4%) 5 (10%)
Spleen (49) (49) (50) (50)
Accessory Spleen 1 (2%)
Atrophy 1 (2%)
Congestion 1 (2%)
Hematopoietic Cell Proliferation 24 (49%) 21 (43%) 18 (36%) 13 (26%)
Hyperplasia, Histiocytic 1 (2%)
Hyperplasia, Lymphoid 6 (12%) 12 (24%) 12 (24%) 6 (12%)
Capsule, Inflammation, Chronic, Focal 1 (2%)
Thymus (46) (48) (44) (47)
Hyperplasia, Lymphoid 5 (11%) 4 (8%) 4 (9%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (49) (49)
Dilatation 1 (2%)
Hyperplasia 1 (2%)
Skin (50) (50) (50) (50)
Ulcer 1 (2%)
Control Dermis, Hyperplasia, Focal 1 (2%)
Control Dermis, Inflammation, Focal 1 (2%) 1 (2%) 1 (2%)
Control Epidermis, Hyperplasia, Focal 1 (2%) 1 (2%)
Epidermis, Hyperplasia, Focal 1 (2%)
Site of Application - Dermis, Fibrosis 1 (2%)
Site of Application - Dermis, Inflammation,
Focal 3 (6%) 2 (4%) 7 (14%) 2 (4%)
Site of Application - Epidermis, Hyperplasia 5 (10%) 3 (6%) 7 (14%) 7 (14%)
Site of Application, Ulcer 2 (4%) 1 (2%)
Subcutaneous Tissue, Angiectasis, Focal 1 (2%)
Subcutaneous Tissue, Edema 1 (2%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM - CONT
Bone (50) (50) (50) (50)
Hyperostosis 3 (6%) 1 (2%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Compression, Focal 2 (4%) 2 (4%) 1 (2%)
Hemorrhage, Focal 1 (2%) 2 (4%)
Infarct 1 (2%)
Inflammation, Focal 1 (2%)
Cerebellum, Hippocampus, Necrosis 1 (2%)
Cerebrum, Atrophy, Focal 1 (2%)
Hippocampus, Necrosis, Acute 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Congestion 2 (4%) 1 (2%) 1 (2%)
Foreign Body 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia, Histiocytic 1 (2%) 1 (2%)
Infiltration Cellular, Polymorphonuclear 2 (4%)
Mineralization, Focal 1 (2%)
Alveolar Epithelium, Hyperplasia, Focal 1 (2%) 2 (4%) 1 (2%) 2 (4%)
Mediastinum, Hyperplasia, Lymphoid 2 (4%)
Nose (50) (50) (49) (50)
Inflammation 1 (2%)
Nasolacrimal Duct, Inflammation 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (47) (48) (49) (49)
Atrophy 1 (2%) 2 (4%)
Phthisis Bulbi 1 (2%)
Cornea, Hyperplasia, Squamous 1 (2%) 1 (2%)
Cornea, Inflammation, Chronic 1 (2%)
Iris, Synechia 1 (2%)
Lens, Cataract 1 (2%)
Harderian Gland (50) (49) (50) (50)
Cyst 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM - CONT
Inflammation 2 (4%)
Epithelium, Hyperplasia, Focal 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (49) (50) (49)
Congestion 1 (2%)
Cyst 1 (2%) 4 (8%)
Hydronephrosis 1 (2%) 1 (2%)
Hyperplasia, Lymphoid 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Infarct 3 (6%) 2 (4%) 1 (2%) 1 (2%)
Infiltration Cellular, Polymorphonuclear 1 (2%)
Infiltration Cellular, Mixed Cell 1 (2%)
Inflammation 1 (2%) 1 (2%)
Metaplasia, Focal, Osseous 5 (10%) 2 (4%) 1 (2%)
Nephropathy 13 (27%) 8 (16%) 11 (22%) 18 (37%)
Capsule, Congestion 1 (2%)
Papilla, Necrosis 1 (2%)
Renal Tubule, Accumulation, Hyaline Droplet 3 (6%) 1 (2%) 2 (4%)
Renal Tubule, Necrosis 1 (2%)
Renal Tubule, Vacuolization Cytoplasmic,
Focal 1 (2%) 1 (2%) 1 (2%)
Urinary Bladder (50) (50) (49) (50)
Angiectasis 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Moribund Sacrifice 5 1 2 5
Natural Death 6 9 10 8
Accidently Killed 1
Survivors
Terminal Sacrifice 38 40 38 36
Moribund Sacrifice 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (45) (42) (43) (41)
Cyst 1 (2%) 1 (2%) 2 (5%)
Epithelium, Degeneration, Hyaline 1 (2%) 1 (2%)
Epithelium, Hyperplasia 1 (2%)
Intestine Small, Duodenum (46) (44) (44) (40)
Ectopic Tissue 1 (2%)
Serosa, Inflammation, Chronic 1 (3%)
Intestine Small, Jejunum (46) (43) (44) (40)
Cyst 1 (3%)
Inflammation, Focal 1 (2%) 1 (2%)
Necrosis 1 (2%)
Peyer's Patch, Hyperplasia, Lymphoid 1 (2%) 1 (2%) 1 (3%)
Intestine Small, Ileum (46) (44) (44) (40)
Peyer's Patch, Hyperplasia, Lymphoid 1 (2%)
Liver (50) (50) (50) (49)
Atrophy 1 (2%)
Basophilic Focus 1 (2%)
Clear Cell Focus 2 (4%) 1 (2%) 1 (2%) 2 (4%)
Eosinophilic Focus 2 (4%) 1 (2%) 1 (2%) 4 (8%)
Fibrosis, Focal 1 (2%)
Hemorrhage, Focal 1 (2%)
Hepatodiaphragmatic Nodule 1 (2%)
Hyperplasia, Focal, Histiocytic 1 (2%)
Infarct 1 (2%) 1 (2%)
Infiltration Cellular, Polymorphonuclear 1 (2%)
Infiltration Cellular, Mixed Cell 8 (16%) 5 (10%) 5 (10%) 6 (12%)
Inflammation, Focal, Granulomatous 1 (2%)
Pigmentation, Focal 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Thrombosis 1 (2%)
Bile Duct, Hyperplasia 1 (2%) 1 (2%)
Capsule, Inflammation, Chronic 1 (2%)
Hepatocyte, Clear Cell Focus 19 (38%) 17 (34%) 12 (24%) 8 (16%)
Hepatocyte, Eosinophilic Focus 2 (4%)
Hepatocyte, Mixed Cell Focus 1 (2%) 2 (4%) 2 (4%)
Hepatocyte, Necrosis, Focal 5 (10%) 3 (6%) 2 (4%) 7 (14%)
Hepatocyte, Vacuolization Cytoplasmic 18 (36%) 17 (34%) 17 (34%) 18 (37%)
Mesentery (49) (49) (50) (50)
Fibrosis, Focal 1 (2%)
Inflammation 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%)
Artery, Inflammation 1 (2%)
Fat, Necrosis, Focal 4 (8%) 2 (4%) 4 (8%) 4 (8%)
Pancreas (49) (50) (49) (49)
Inflammation, Focal 1 (2%)
Necrosis, Focal 1 (2%) 1 (2%)
Acinus, Atrophy, Focal 3 (6%)
Serosa, Inflammation, Chronic 1 (2%)
Salivary Glands (50) (50) (50) (50)
Atrophy 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Diverticulum 1 (2%)
Erosion 1 (2%)
Inflammation, Focal 1 (2%) 1 (2%)
Ulcer 1 (2%)
Epithelium, Cyst 1 (2%)
Epithelium, Hyperplasia 2 (4%) 2 (4%) 3 (6%) 2 (4%)
Stomach, Glandular (50) (47) (48) (47)
Erosion 4 (8%) 1 (2%) 1 (2%)
Tooth (18) (11) (15) (12)
Malformation 18 (100%) 11 (100%) 15 (100%) 12 (100%)
Peridontal Tissue, Inflammation, Chronic 1 (7%)
Pulp, Inflammation 1 (7%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Cardiomyopathy 1 (2%) 1 (2%)
Infiltration Cellular, Mixed Cell 1 (2%)
Inflammation, Chronic, Focal 1 (2%)
Thrombosis 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM - CONT
Artery, Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (49)
Accessory Adrenal Cortical Nodule 3 (6%) 2 (4%) 2 (4%) 2 (4%)
Cytoplasmic Alteration, Focal 9 (18%) 5 (10%) 7 (14%) 4 (8%)
Degeneration, Cystic 1 (2%)
Hyperplasia, Focal, Histiocytic 1 (2%)
Hypertrophy 1 (2%)
Vacuolization Cytoplasmic, Focal 1 (2%)
Adrenal Medulla (49) (50) (50) (49)
Angiectasis 1 (2%)
Hyperplasia, Focal 1 (2%)
Islets, Pancreatic (49) (50) (49) (50)
Hyperplasia 2 (4%) 2 (4%) 2 (4%) 1 (2%)
Parathyroid Gland (49) (50) (46) (47)
Cyst 1 (2%) 2 (4%) 1 (2%)
Pituitary Gland (48) (47) (50) (49)
Cyst 1 (2%) 2 (4%) 3 (6%) 3 (6%)
Pars Distalis, Cytoplasmic Alteration, Focal 1 (2%) 5 (10%)
Pars Distalis, Hyperplasia, Focal 1 (2%)
Thyroid Gland (49) (50) (50) (50)
C-Cell, Hyperplasia 1 (2%) 3 (6%)
Follicle, Degeneration, Cystic, Focal 4 (8%) 6 (12%) 8 (16%) 6 (12%)
Follicular Cell, Hyperplasia, Focal 7 (14%) 7 (14%) 8 (16%) 3 (6%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (3) (2)
Hemorrhage 1 (50%)
Abdominal, Cyst 1 (33%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Granuloma Sperm 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Spermatocele 1 (2%)
Preputial Gland (50) (50) (50) (50)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Cyst 2 (4%)
Degeneration, Cystic 3 (6%) 1 (2%) 1 (2%) 4 (8%)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Chronic 11 (22%) 8 (16%) 10 (20%) 6 (12%)
Prostate (50) (50) (50) (50)
Inflammation 1 (2%) 2 (4%)
Epithelium, Hyperplasia, Focal 2 (4%) 1 (2%)
Seminal Vesicle (50) (50) (50) (50)
Cyst 1 (2%)
Testes (50) (50) (50) (50)
Atrophy 1 (2%) 1 (2%)
Interstitial Cell, Hyperplasia, Focal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (50)
Hyperplasia 9 (18%) 13 (26%) 12 (24%) 7 (14%)
Thrombosis 1 (2%)
Lymph Node (6) (5) (5) (4)
Bronchial, Hyperplasia, Lymphoid 1 (20%)
Iliac, Hyperplasia, Lymphoid 1 (25%)
Inguinal, Hyperplasia, Lymphoid 2 (33%) 3 (60%) 4 (80%) 1 (25%)
Mediastinal, Hyperplasia, Lymphoid 1 (20%)
Pancreatic, Hyperplasia, Lymphoid 1 (20%) 1 (20%) 1 (25%)
Lymph Node, Mandibular (47) (48) (47) (47)
Hyperplasia, Histiocytic 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Lymph Node, Mesenteric (50) (48) (49) (48)
Ectasia 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hemorrhage 3 (6%) 1 (2%) 3 (6%)
Hyperplasia, Lymphoid 3 (6%) 2 (4%) 4 (8%) 2 (4%)
Spleen (49) (50) (50) (47)
Atrophy 1 (2%) 1 (2%)
Fibrosis, Focal 1 (2%)
Hematopoietic Cell Proliferation 15 (31%) 13 (26%) 14 (28%) 13 (28%)
Hyperplasia, Lymphoid 2 (4%) 5 (10%) 1 (2%) 1 (2%)
Thrombosis 1 (2%)
Capsule, Inflammation, Chronic 1 (2%)
Thymus (47) (44) (47) (46)
Cyst 2 (4%) 1 (2%) 2 (4%)
Hyperplasia, Lymphoid 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Ulcer 1 (2%)
Epidermis, Hyperplasia, Focal 1 (2%) 1 (2%)
Site of Application - Dermis, Inflammation,
Focal 2 (4%) 2 (4%) 9 (18%) 1 (2%)
Site of Application - Epidermis, Hyperplasia 2 (4%) 3 (6%) 10 (20%) 1 (2%)
Site of Application, Ulcer 1 (2%) 1 (2%)
Subcutaneous Tissue, Angiectasis, Focal 1 (2%)
Subcutaneous Tissue, Edema 2 (4%)
Subcutaneous Tissue, Inflammation, Chronic,
Focal 1 (2%)
Subcutaneous Tissue, Thrombosis 1 (2%)
Subcutaneous Tissue, Site of Application,
Infiltration Cellular 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Hyperostosis 2 (4%) 2 (4%) 1 (2%)
Skeletal Muscle (2) (2) (2) (5)
Inflammation, Chronic 1 (20%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Congestion 1 (2%) 1 (2%)
Hyperplasia, Histiocytic 1 (2%) 1 (2%) 4 (8%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Inflammation, Chronic, Focal 1 (2%)
Alveolar Epithelium, Hyperplasia, Focal 4 (8%) 2 (4%) 1 (2%) 3 (6%)
Mediastinum, Hyperplasia, Lymphoid 1 (2%)
Nose (49) (50) (50) (50)
Inflammation 2 (4%) 1 (2%)
Nasolacrimal Duct, Cyst 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:10:57
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Nasolacrimal Duct, Hyperplasia, Focal 1 (2%) 2 (4%) 1 (2%)
Nasolacrimal Duct, Inflammation 1 (2%) 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (46) (46) (47) (44)
Atrophy 1 (2%)
Inflammation 1 (2%)
Cornea, Hyperplasia, Squamous 1 (2%) 1 (2%)
Cornea, Inflammation, Chronic 2 (4%) 3 (7%) 1 (2%) 3 (7%)
Cornea, Necrosis, Focal 1 (2%) 1 (2%)
Retrobulbar, Inflammation 1 (2%)
Harderian Gland (50) (50) (50) (50)
Degeneration, Cystic, Focal 1 (2%)
Inflammation 1 (2%) 1 (2%)
Epithelium, Hyperplasia, Focal 3 (6%) 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (48) (48) (50) (48)
Cyst 3 (6%) 10 (21%) 5 (10%) 3 (6%)
Hydronephrosis 2 (4%) 1 (2%)
Infarct 2 (4%) 3 (6%) 1 (2%) 1 (2%)
Infiltration Cellular, Mixed Cell 1 (2%)
Inflammation 3 (6%)
Metaplasia, Focal, Osseous 4 (8%) 2 (4%) 1 (2%)
Nephropathy 46 (96%) 44 (92%) 41 (82%) 40 (83%)
Pelvis, Dilatation 1 (2%)
Renal Tubule, Hyperplasia, Focal 2 (4%) 3 (6%) 1 (2%)
Urinary Bladder (50) (50) (49) (50)
Inflammation 1 (2%) 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------